Abstract:Immunotherapies that target PD-1/PD-L1 axis have shown unprecedented success in awide variety of human cancers. PD-1 is one of the key coinhibitory receptors expressed on T cells upon T cell activation. After engagement with its ligands, mainly PD-L1, PD-1 is activated and recruits the phosphatase SHP-2 in proximity to T cell receptor (TCR) and CD28 signaling. This event results in dephosphorylation and attenuation of key molecules in TCR and CD28 pathway, leading to inhibition of T cell proliferation, activation, cytokine production, altered metabolism and cytotoxic T lymphocytes (CTLs) killer functions, and eventual death of activated T cells. Bodies evolve coinhibitory pathways controllingTcell response magnitude and duration to limit tissue damage and maintain self-tolerance. However, tumor cells hijack these inhibitory pathways to escape host immune surveillance by overexpression of PD-L1. This provides the scientific rationale for clinical application of immune checkpoint inhibitors in oncology. The aberrantly high expression of PD-L1 in tumor microenvironment (TME) can be attributable to the "primary" activation of multiple oncogenic signaling and the "secondary" induction by inflammatory factors such as IFN-.. Clinically, antibodies targeting PD-1/PD-L1 reinvigorate the "exhausted" T cells in TME and show remarkable objective response and durable remission with acceptable toxicity profile in large numbers of tumors such as melanoma, lymphoma, and mismatch-repair deficient tumors. Nevertheless, most patients are still refractory to anti-PD-1/PD-L1 therapy. Identifying the predictive biomarkers and design rational PD-1-based combination therapy become the priorities in cancer immunotherapy. PD-L1 expression, cytotoxic T lymphocytes infiltration, and tumor mutation burden (TMB) are generally considered as the most important factors affecting the effectiveness of PD-1/PD-L1 blockade. The revolution in cancer immunotherapy achieved by PD-1/PD-L1 blockade offers the paradigm for scientific translation from bench to bedside. The next decades will without doubt witness the renaissance of immunotherapy.

Optimization of cancer immunotherapy on the basis of programmed death ligand-1 distribution and function

Optimization of Cancer Immunotherapy on the Basis of Programmed Death Ligand‐1 Distribution and Function

PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations

PD-1 regulation in immune homeostasis and immunotherapy

Strategies targeting PD-L1 expression and associated opportunities for cancer combination therapy

Research progress of anti-PD-1 / PD-L1 immunotherapy biomarkers

PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy

Generation, secretion and degradation of cancer immunotherapy target PD-L1

Roles of PD-1/PD-L1 Pathway: Signaling, Cancer, and Beyond.

Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation

Programmed Death 1/programmed Death Ligand 1 Signaling Pathway in Tumor Immunotherapy: an Update

Immune Checkpoint Blockade in Cancer Immunotherapy: Mechanisms, Clinical Outcomes, and Safety Profiles of PD-1/PD-L1 Inhibitors

Application of PD-1 Blockade in Cancer Immunotherapy

Programmed Cell Death Protein 1 (PD-1) and Programmed Cell Death Ligand 1 (PD-L1) Immunotherapy: A Promising Breakthrough in Cancer Therapeutics

Various Uses of PD1/PD-L1 Inhibitor in Oncology: Opportunities and Challenges

Looking for the Optimal PD-1/PD-L1 Inhibitor in Cancer Treatment: A Comparison in Basic Structure, Function, and Clinical Practice

The role of PD-1/PD-L1 and application of immune-checkpoint inhibitors in human cancers

Combination strategies with PD-1/PD-L1 blockade: current advances and future directions

Advances of PD-1/PD-L1 inhibitors in tumor immunotherapy

Immune Landscape and Therapeutic Strategies: New Insights into PD-L1 in Tumors

The opportunities and challenges in immunotherapy: Insights from the regulation of PD-L1 in cancer cells.